BTIG analyst Ryan Zimmerman initiated coverage of Staar Surgical with a Buy rating and $46 price target. With Lasik struggling to grow and demographics adding, Staar Surgical's opportunity "has never been better," Zimmerman tells investors in a research note. The analyst believes that with little upfront capital costs, Staar offers an attractive economic proposal to ophthalmologists. He sees potential upside to the company's 25% annual sales growth target through fiscal 2022 on increasing penetration of existing markets, entry into new markets, new products and new indications.